12:00 AM
 | 
Nov 15, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zebinix eslicarbazepine acetate regulatory update

The Scottish Medicines Consortium approved the restricted use of Zebinix eslicarbazepine from Bial-Portela as an adjunct therapy for epilepsy in adults with partial-onset seizures with or without secondary generalization to only include those with highly refractory...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >